1256836-96-0

Basic information

• Product Name: methyl 3-fluoro-5-hydroxypyridine-2-carboxylate
• CAS NO: 1256836-96-0
• Molecular Weight: 171.128
• Mol File: 1256836-96-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 3-fluoro-5-hydroxypyridine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-fluoro-5-hydroxypyridine-2-carboxylate(1256836-96-0)
• EPA Substance Registry System: methyl 3-fluoro-5-hydroxypyridine-2-carboxylate(1256836-96-0)

Safety Data

• Hazardous Substances Data: 1256836-96-0(Hazardous Substances Data)

Upstream product

• 745784-04-7 3,5-difluoropyridine-2-carboxylic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 886373-28-0 5-bromo-3-fluoropyridine-2-carbonitrile 
• 669066-91-5 5-bromo-3-fluoro-pyridine-2-carboxylic acid 
• 1211538-72-5 methyl 5-bromo-3-fluoro-pyridine-2-carboxylate 

Relevant articles and documents

PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULPHUR CONTAINING SUBSTITUENTS

Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.